CDKN2A and uveal melanoma: Russo et al. proposed that inactivating mutations of the cyclin-dependent kinase inhibitor 2A (CDKN2A) through promoter methylation or the loss of the 9p region could be involved in triggering the metastatic progression of uveal melanoma [64].